Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

被引：0
|
作者：
Amengual, Jennifer E. [1 ]
Johannet, Paul M. [1 ]
Jones, Simon S. [2 ]
O'Connor, Owen A. [1 ]
机构：
[1] Columbia Univ, Ctr Lymphoid Malignancies, Med Ctr, New York, NY USA
[2] Acetylon Pharmaceut, Boston, MA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1650.1650
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1650
引用
收藏
页数：2
相关论文
共 26 条
  • [1] Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
    Amengual, Jennifer E.
    Johannet, Paul
    Lombardo, Maximilian
    Zullo, Kelly
    Hoehn, Daniela
    Bhagat, Govind
    Scotto, Luigi
    Jirau-Serrano, Xavier
    Radeski, Dejan
    Heinen, Jennifer
    Jiang, Hongfeng
    Cremers, Serge
    Zhang, Yuan
    Jones, Simon
    O'Connor, Owen A.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (20) : 4663 - 4675
  • [2] Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines
    Cosenza, Maria
    Civallero, Monica
    Pozzi, Samantha
    Marcheselli, Luigi
    Sacchi, Stefano
    [J]. BLOOD, 2014, 124 (21)
  • [3] Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    Santo, Loredana
    Hideshima, Teru
    Kung, Andrew L.
    Tseng, Jen-Chieh
    Tamang, David
    Yang, Min
    Jarpe, Matthew
    van Duzer, John H.
    Mazitschek, Ralph
    Ogier, Walter C.
    Cirstea, Diana
    Rodig, Scott
    Eda, Homare
    Scullen, Tyler
    Canavese, Miriam
    Bradner, James
    Anderson, Kenneth C.
    Jones, Simon S.
    Raje, Noopur
    [J]. BLOOD, 2012, 119 (11) : 2579 - 2589
  • [4] Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma
    Santo, Loredana
    Hideshima, Teru
    Kung, Andrew L.
    Tseng, Jen-Chieh
    Tamang, David
    Yang, Min
    Jarpe, Matthew
    van Duzer, John H.
    Mazitschek, Ralph
    Ogier, Walter C.
    Cirstea, Diana D.
    Rodig, Scott
    Eda, Homare
    Scullen, Tyler A.
    Canavese, Miriam
    Bradner, James E.
    Anderson, Kenneth C.
    Jones, Simon
    Raje, Noopur S.
    [J]. BLOOD, 2011, 118 (21) : 1256 - 1256
  • [5] Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bendamustine Is Effective in Preclinical Studies in Lymphoma Cell Lines
    Cosenza, Maria
    Civallero, Monica
    Quayle, Steven N.
    Sacchi, Stefano
    Pozzi, Samantha
    [J]. BLOOD, 2016, 128 (22)
  • [6] ACY-1215, a First-In-Class Selective Inhibitor Of HDAC6, Demonstrates Significant Synergy With Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM)
    Quayle, Steven N.
    Jones, Simon S.
    [J]. BLOOD, 2013, 122 (21)
  • [7] Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM)
    Santo, Loredana
    Hideshima, Teru
    Kung, Andrew L.
    Jarpe, Matthew
    Cirstea, Diana
    Patel, Kishan
    Pozzi, Samantha
    Tseng, Jen C.
    Rodig, Scott J.
    Bradner, James
    Anderson, Kenneth C.
    Jones, Simon
    Raje, Noopur
    [J]. BLOOD, 2010, 116 (21) : 1235 - 1236
  • [8] The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells
    Lee, Dong Hoon
    Won, Hye-Rim
    Ryu, Hyun-Wook
    Han, Jung Min
    Kwon, So Hee
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (02) : 844 - 854
  • [9] Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
    Raje, Noopur
    Hari, Parameswaran N.
    Vogl, Dan T.
    Jagannath, Sundar
    Orlowski, Robert Z.
    Supko, Jeffrey G.
    Stephenson, Patricia
    Jones, Simon S.
    Wheeler, Catherine
    Lonial, Sagar
    [J]. BLOOD, 2012, 120 (21)
  • [10] First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma
    Amengual, Jennifer E.
    Lue, Jennifer K.
    Ma, Helen
    Lichtenstein, Renee
    Shah, Bijal
    Cremers, Serge
    Jones, Simon
    Sawas, Ahmed
    [J]. ONCOLOGIST, 2021, 26 (03): : 184 - e366
123